BD (Becton, Dickinson and Company) announced the expansion of its diagnostic offerings in Europe following the In Vitro Diagnostic Medical Device Regulation (IVDR) certification of two VIASURE assays, developed by Certest Biotec, for use on the BD MAX™ System. The newly certified assays include a respiratory virus detection kit and an HSV-1, HSV-2 & Treponema pallidum assay, enabling clinical laboratories to rapidly and accurately detect a range of pathogens using BD's automated molecular platform. This certification allows BD to enhance its respiratory and sexually transmitted infection diagnostic menu in European markets.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BD - Becton, Dickinson and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: NY47471) on December 15, 2025, and is solely responsible for the information contained therein.